The goal of the Waldenstrom’s Macroglobulinemia Foundation of Canada is to offer you the resources to better understand this rare disease, to give you the knowledge you will need to move forward and to connect with the people who can guide you and your families on this journey.
We will endeavour to provide you with the most current information on treatment options, clinical trials, and medical tests. The WMFC will have the latest information on the current research in Waldenstrom’s Macroglobulinemia in our quest to find the cause and ultimately a cure for this rare cancer.
WMFC was founded on giving hope and inspiration to everyone diagnosed with Waldenstrom’s Macroglobulinemia.
We provide information, resources, a communications network, and experience on how to live with WM. We provide encouragement to those affected by this rare blood cancer. The WMFC is a non-profit, all-volunteer organization, developed and financed almost entirely by patients and their friends and families. As well as providing information to WM patients and care-givers. WMFC funds important research into this orphan disease — research that can help improve available treatments and may some day lead to a cure.
If you are not already familiar with it, you should check out the excellent resources at our organization’s parent site, the IWMF website. This is a public website available to everyone. There you will also find information about WM and its treatment. In addition to its public website information, the IWMF also publishes, for its members, a newlsetter (The Torch).
After diagnosis with WM, we often feel alone and afraid. By joining our focused interest, commitment and energy together, we can make a dramatic difference in each other’s daily lives. We can help each other learn more about this disease by sharing our symptoms and treatment results. We can learn how to take control of our treatment decisions. We can seek recognition and attention from government agencies, and more importantly, we can sponsor research towards an ultimate cure.